LTZ Therapeutics Secures $38M to Advance Myeloid Engager Immunotherapy Pipeline

LTZ Therapeutics, a US-headquartered clinical-stage, immunotherapy-focused biotechnology company, has raised $38 million in an oversubscribed financing round to advance its Universal Myeloid Cell Engager (U-MCE) immunotherapy platform, with a focus on its lead candidate LTZ-301, currently in a phase 1 clinical study. The round was led by GL Ventures, with participation from a sovereign wealth fund and existing investors, bringing the company’s total funding to approximately $130 million since its founding in 2022.¹

The funding will support pipeline development, including the ongoing phase 1 study of LTZ-301 in relapsed or refractory non-Hodgkin lymphoma (NHL), as well as an investigational new drug (IND) application and phase 1 initiation for a second candidate, LTZ-232. The LTZ-301 trial is actively enrolling patients at multiple clinical sites in the United States.

“This financing empowers us to translate the potential of our Myeloid Engager Platform into tangible clinical impact for patients,” said Robert Li, PhD, founder and CEO of LTZ Therapeutics, in a company press release.¹

What is driving development of myeloid engager immunotherapies?

The company’s U-MCE platform is designed to target myeloid cells, particularly monocytes and macrophages, to enhance anti-tumor immune responses. LTZ’s approach is based on reverse translational science and a focus on tumor microenvironment (TME) biology. Macrophages are among the most prevalent immune cell populations within the TME across hematologic and solid tumors.²

By enhancing the phagocytic activity of these cells, the company’s platform aims to improve immune-mediated tumor clearance. LTZ is also exploring applications beyond oncology, including autoimmune diseases, although current clinical efforts are focused on cancer indications.

How does LTZ-301 target B-cell malignancies?

LTZ-301 is a bispecific antibody designed to deplete CD79b-positive B cells by redirecting monocytes and macrophages to these targets. CD79b is highly expressed in B-cell malignancies, ^including cases resistant to CD19- or CD20-directed therapies.³

According to the company, preclinical studies demonstrated pharmacologic activity in both in vitro and in vivo models, along with a favorable safety profile. The ongoing phase 1 study is evaluating LTZ-301 in patients with relapsed or refractory NHL.

“The transition of its lead asset LTZ-301 into [p]hase 1, alongside the upcoming IND filing for LTZ-232, reflects the team's operational efficiency and proven ability to execute on this first-in-class modality,” GL Ventures said in a statement.¹

What role does leadership expansion play in pipeline advancement?

In conjunction with the financing, LTZ Therapeutics appointed Erin Lavelle as an independent member of its board of directors. Lavelle brings more than 25 years of experience across pharmaceutical and biotechnology companies, including roles in both private and public organizations. Most recently, she served as chief operating officer and chief financial officer of ProfoundBio, where she led efforts related to a $1.8 billion acquisition and prior financing activities.

The company indicated that the board appointment is intended to support strategic operations as LTZ advances its clinical programs and expands globally.

How are next-generation bispecific antibodies advancing clinical precision in oncology?

Momentum continues in bispecific antibody development, particularly in efforts to enhance target specificity while minimizing off-target toxicity. Emerging formats are being engineered to improve binding affinity and conditional activation within the tumor microenvironment, enabling more precise immune engagement.⁴

In early-stage studies, several investigational bispecifics have demonstrated encouraging efficacy signals in hematologic malignancies and solid tumors, alongside manageable safety profiles.⁵ These advances emphasize a broader industry shift toward multifunctional antibody platforms, aligning with LTZ Therapeutics’ strategy of leveraging immune cell redirection to improve therapeutic outcomes in difficult-to-treat cancers.

References

1. LTZ Therapeutics. LTZ Therapeutics raises $38 million in support of advancing myeloid engager immunotherapy pipeline. Published May 6, 2026. Accessed May 6, 2026. https://ltztherapeutics.com/html/news/139.html
2. Bied M, Ho WW, Ginhoux, F, Blériot C. Roles of macrophages in tumor development: a spatiotemporal perspective. Cell Mol Immunol 2023;20:983–992. doi: 10.1038/s41423-023-01061-6
3. Chu F, Cao J, Liu J, et al. Chimeric antigen receptor T cells to target CD79b in B-cell lymphomas. J Immunother Cancer. 2023;11(11):e007515. doi: 10.1136/jitc-2023-007515 
4. Sidewinder Therapeutics. Sidewinder Therapeutics Announces $137 Million Series B Financing to Advance Precision Bispecific ADCs into Clinical Development for Cancer. Published April 8, 2026. Accessed May 6, 2026. https://sidewinderbio.com/news/sidewinder-therapeutics-announces-137-million-series-b-financing-to-advance-precision-bispecific-adcs-into-clinical-development-for-cancer/
5. Zhang W, Wang M, Ji C, et al. Macrophage polarization in the tumor microenvironment: Emerging roles and therapeutic potentials. Biomed. Pharmacother. 2024;177:116930. doi: 10.1016/j.biopha.2024.116930